nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—Corticosteroid Hormone Receptor Agonists—Prednisone—systemic scleroderma	0.26	1	CiPCiCtD
Fluocinolone Acetonide—Mometasone—systemic scleroderma	0.222	1	CrCtD
Fluocinolone Acetonide—psoriasis—systemic scleroderma	0.216	1	CtDrD
Fluocinolone Acetonide—NR3C1—Mometasone—systemic scleroderma	0.0696	0.759	CbGbCtD
Fluocinolone Acetonide—NR3C1—Prednisone—systemic scleroderma	0.0222	0.241	CbGbCtD
Fluocinolone Acetonide—Fluticasone furoate—Mometasone—systemic scleroderma	0.00631	0.0356	CrCrCtD
Fluocinolone Acetonide—Flumethasone Pivalate—Mometasone—systemic scleroderma	0.00567	0.032	CrCrCtD
Fluocinolone Acetonide—Halobetasol Propionate—Mometasone—systemic scleroderma	0.00549	0.031	CrCrCtD
Fluocinolone Acetonide—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00549	0.031	CrCrCtD
Fluocinolone Acetonide—Difluprednate—Mometasone—systemic scleroderma	0.00549	0.031	CrCrCtD
Fluocinolone Acetonide—Clocortolone—Mometasone—systemic scleroderma	0.00516	0.0291	CrCrCtD
Fluocinolone Acetonide—Fluocinonide—Mometasone—systemic scleroderma	0.00516	0.0291	CrCrCtD
Fluocinolone Acetonide—Beclomethasone—Mometasone—systemic scleroderma	0.00516	0.0291	CrCrCtD
Fluocinolone Acetonide—Fluocortolone—Mometasone—systemic scleroderma	0.00502	0.0283	CrCrCtD
Fluocinolone Acetonide—Alclometasone—Mometasone—systemic scleroderma	0.00488	0.0275	CrCrCtD
Fluocinolone Acetonide—Budesonide—Mometasone—systemic scleroderma	0.00475	0.0268	CrCrCtD
Fluocinolone Acetonide—Amcinonide—Mometasone—systemic scleroderma	0.00475	0.0268	CrCrCtD
Fluocinolone Acetonide—Desonide—Mometasone—systemic scleroderma	0.00462	0.0261	CrCrCtD
Fluocinolone Acetonide—Flunisolide—Mometasone—systemic scleroderma	0.00462	0.0261	CrCrCtD
Fluocinolone Acetonide—Diflorasone—Mometasone—systemic scleroderma	0.00462	0.0261	CrCrCtD
Fluocinolone Acetonide—Fludrocortisone—Mometasone—systemic scleroderma	0.00462	0.0261	CrCrCtD
Fluocinolone Acetonide—Clobetasol propionate—Mometasone—systemic scleroderma	0.00462	0.0261	CrCrCtD
Fluocinolone Acetonide—Paramethasone—Mometasone—systemic scleroderma	0.00451	0.0254	CrCrCtD
Fluocinolone Acetonide—Desoximetasone—Mometasone—systemic scleroderma	0.0044	0.0248	CrCrCtD
Fluocinolone Acetonide—Fluorometholone—Mometasone—systemic scleroderma	0.00429	0.0242	CrCrCtD
Fluocinolone Acetonide—Triamcinolone—Mometasone—systemic scleroderma	0.00429	0.0242	CrCrCtD
Fluocinolone Acetonide—Fluprednidene Acetate—Mometasone—systemic scleroderma	0.00429	0.0242	CrCrCtD
Fluocinolone Acetonide—Betamethasone—Mometasone—systemic scleroderma	0.0042	0.0237	CrCrCtD
Fluocinolone Acetonide—Rimexolone—Mometasone—systemic scleroderma	0.0042	0.0237	CrCrCtD
Fluocinolone Acetonide—Dexamethasone—Mometasone—systemic scleroderma	0.0042	0.0237	CrCrCtD
Fluocinolone Acetonide—Methylprednisolone—Mometasone—systemic scleroderma	0.00401	0.0226	CrCrCtD
Fluocinolone Acetonide—Prednisolone—Mometasone—systemic scleroderma	0.00393	0.0222	CrCrCtD
Fluocinolone Acetonide—Fluocortolone—Prednisone—systemic scleroderma	0.00273	0.0154	CrCrCtD
Fluocinolone Acetonide—Alclometasone—Prednisone—systemic scleroderma	0.00266	0.015	CrCrCtD
Fluocinolone Acetonide—Budesonide—Prednisone—systemic scleroderma	0.00259	0.0146	CrCrCtD
Fluocinolone Acetonide—Amcinonide—Prednisone—systemic scleroderma	0.00259	0.0146	CrCrCtD
Fluocinolone Acetonide—Diflorasone—Prednisone—systemic scleroderma	0.00252	0.0142	CrCrCtD
Fluocinolone Acetonide—Fludrocortisone—Prednisone—systemic scleroderma	0.00252	0.0142	CrCrCtD
Fluocinolone Acetonide—Flunisolide—Prednisone—systemic scleroderma	0.00252	0.0142	CrCrCtD
Fluocinolone Acetonide—Clobetasol propionate—Prednisone—systemic scleroderma	0.00252	0.0142	CrCrCtD
Fluocinolone Acetonide—Desonide—Prednisone—systemic scleroderma	0.00252	0.0142	CrCrCtD
Fluocinolone Acetonide—Paramethasone—Prednisone—systemic scleroderma	0.00246	0.0139	CrCrCtD
Fluocinolone Acetonide—Desoximetasone—Prednisone—systemic scleroderma	0.0024	0.0135	CrCrCtD
Fluocinolone Acetonide—Fluorometholone—Prednisone—systemic scleroderma	0.00234	0.0132	CrCrCtD
Fluocinolone Acetonide—Triamcinolone—Prednisone—systemic scleroderma	0.00234	0.0132	CrCrCtD
Fluocinolone Acetonide—Mometasone—Prednisone—systemic scleroderma	0.00234	0.0132	CrCrCtD
Fluocinolone Acetonide—Fluprednidene Acetate—Prednisone—systemic scleroderma	0.00234	0.0132	CrCrCtD
Fluocinolone Acetonide—Dexamethasone—Prednisone—systemic scleroderma	0.00229	0.0129	CrCrCtD
Fluocinolone Acetonide—Betamethasone—Prednisone—systemic scleroderma	0.00229	0.0129	CrCrCtD
Fluocinolone Acetonide—Rimexolone—Prednisone—systemic scleroderma	0.00229	0.0129	CrCrCtD
Fluocinolone Acetonide—Methylprednisolone—Prednisone—systemic scleroderma	0.00219	0.0123	CrCrCtD
Fluocinolone Acetonide—Prednisolone—Prednisone—systemic scleroderma	0.00214	0.0121	CrCrCtD
Fluocinolone Acetonide—PLA2G4A—Enalapril—Captopril—systemic scleroderma	0.000476	0.469	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Raltitrexed—Methotrexate—systemic scleroderma	0.000263	0.259	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Enalapril—Lisinopril—systemic scleroderma	0.000157	0.155	CbGdCrCtD
Fluocinolone Acetonide—Influenza—Mycophenolic acid—systemic scleroderma	7.51e-05	0.00231	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Azathioprine—systemic scleroderma	7.44e-05	0.00229	CcSEcCtD
Fluocinolone Acetonide—Infestation—Azathioprine—systemic scleroderma	7.44e-05	0.00229	CcSEcCtD
Fluocinolone Acetonide—Back pain—Mometasone—systemic scleroderma	7.33e-05	0.00226	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Leflunomide—systemic scleroderma	7.32e-05	0.00225	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Mycophenolate mofetil—systemic scleroderma	7.24e-05	0.00223	CcSEcCtD
Fluocinolone Acetonide—Oedema—Pentoxifylline—systemic scleroderma	7.17e-05	0.00221	CcSEcCtD
Fluocinolone Acetonide—Infection—Pentoxifylline—systemic scleroderma	7.12e-05	0.00219	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Prednisone—systemic scleroderma	7.09e-05	0.00218	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Mycophenolate mofetil—systemic scleroderma	7.03e-05	0.00216	CcSEcCtD
Fluocinolone Acetonide—Infestation—Leflunomide—systemic scleroderma	7.02e-05	0.00216	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Leflunomide—systemic scleroderma	7.02e-05	0.00216	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Lisinopril—systemic scleroderma	7e-05	0.00215	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Mycophenolic acid—systemic scleroderma	6.98e-05	0.00215	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Mycophenolate mofetil—systemic scleroderma	6.86e-05	0.00211	CcSEcCtD
Fluocinolone Acetonide—Influenza—Lisinopril—systemic scleroderma	6.77e-05	0.00208	CcSEcCtD
Fluocinolone Acetonide—Abscess—Methotrexate—systemic scleroderma	6.77e-05	0.00208	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Captopril—systemic scleroderma	6.76e-05	0.00208	CcSEcCtD
Fluocinolone Acetonide—Cataract—Prednisone—systemic scleroderma	6.73e-05	0.00207	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Mycophenolic acid—systemic scleroderma	6.7e-05	0.00206	CcSEcCtD
Fluocinolone Acetonide—Infestation—Mycophenolic acid—systemic scleroderma	6.7e-05	0.00206	CcSEcCtD
Fluocinolone Acetonide—Cough—Mometasone—systemic scleroderma	6.61e-05	0.00204	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Leflunomide—systemic scleroderma	6.59e-05	0.00203	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Pentoxifylline—systemic scleroderma	6.53e-05	0.00201	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Captopril—systemic scleroderma	6.52e-05	0.00201	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Mometasone—systemic scleroderma	6.45e-05	0.00199	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Leflunomide—systemic scleroderma	6.32e-05	0.00194	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Lisinopril—systemic scleroderma	6.29e-05	0.00193	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Mycophenolic acid—systemic scleroderma	6.28e-05	0.00193	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Captopril—systemic scleroderma	6.27e-05	0.00193	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Leflunomide—systemic scleroderma	6.19e-05	0.00191	CcSEcCtD
Fluocinolone Acetonide—Infection—Mometasone—systemic scleroderma	6.15e-05	0.00189	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Mycophenolic acid—systemic scleroderma	6.03e-05	0.00185	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Azathioprine—systemic scleroderma	6.02e-05	0.00185	CcSEcCtD
Fluocinolone Acetonide—Influenza—Mycophenolate mofetil—systemic scleroderma	5.93e-05	0.00182	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	5.91e-05	0.00182	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Azathioprine—systemic scleroderma	5.9e-05	0.00181	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Leflunomide—systemic scleroderma	5.89e-05	0.00181	CcSEcCtD
Fluocinolone Acetonide—Cough—Captopril—systemic scleroderma	5.81e-05	0.00179	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Methotrexate—systemic scleroderma	5.81e-05	0.00179	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Mycophenolic acid—systemic scleroderma	5.79e-05	0.00178	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Leflunomide—systemic scleroderma	5.68e-05	0.00175	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Captopril—systemic scleroderma	5.67e-05	0.00174	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Pentoxifylline—systemic scleroderma	5.67e-05	0.00174	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Lisinopril—systemic scleroderma	5.66e-05	0.00174	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Mometasone—systemic scleroderma	5.64e-05	0.00173	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Mycophenolic acid—systemic scleroderma	5.62e-05	0.00173	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Leflunomide—systemic scleroderma	5.57e-05	0.00171	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Leflunomide—systemic scleroderma	5.52e-05	0.0017	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Leflunomide—systemic scleroderma	5.49e-05	0.00169	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Lisinopril—systemic scleroderma	5.43e-05	0.00167	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	5.42e-05	0.00167	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Leflunomide—systemic scleroderma	5.37e-05	0.00165	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Mycophenolic acid—systemic scleroderma	5.31e-05	0.00163	CcSEcCtD
Fluocinolone Acetonide—Back pain—Leflunomide—systemic scleroderma	5.31e-05	0.00163	CcSEcCtD
Fluocinolone Acetonide—Pain—Mometasone—systemic scleroderma	5.29e-05	0.00163	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	5.29e-05	0.00163	CcSEcCtD
Fluocinolone Acetonide—Infestation—Mycophenolate mofetil—systemic scleroderma	5.29e-05	0.00163	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Pentoxifylline—systemic scleroderma	5.28e-05	0.00163	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Mycophenolic acid—systemic scleroderma	5.27e-05	0.00162	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Mycophenolic acid—systemic scleroderma	5.23e-05	0.00161	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Leflunomide—systemic scleroderma	5.17e-05	0.00159	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Pentoxifylline—systemic scleroderma	5.07e-05	0.00156	CcSEcCtD
Fluocinolone Acetonide—Back pain—Mycophenolic acid—systemic scleroderma	5.06e-05	0.00156	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Mycophenolate mofetil—systemic scleroderma	4.96e-05	0.00153	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Captopril—systemic scleroderma	4.95e-05	0.00152	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Azathioprine—systemic scleroderma	4.95e-05	0.00152	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Mycophenolic acid—systemic scleroderma	4.93e-05	0.00152	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Leflunomide—systemic scleroderma	4.93e-05	0.00152	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Pentoxifylline—systemic scleroderma	4.91e-05	0.00151	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Mometasone—systemic scleroderma	4.89e-05	0.0015	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Lisinopril—systemic scleroderma	4.88e-05	0.0015	CcSEcCtD
Fluocinolone Acetonide—Cough—Leflunomide—systemic scleroderma	4.79e-05	0.00147	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Lisinopril—systemic scleroderma	4.79e-05	0.00147	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Mycophenolate mofetil—systemic scleroderma	4.76e-05	0.00146	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Lisinopril—systemic scleroderma	4.75e-05	0.00146	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Pentoxifylline—systemic scleroderma	4.74e-05	0.00146	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Lisinopril—systemic scleroderma	4.71e-05	0.00145	CcSEcCtD
Fluocinolone Acetonide—Erythema—Lisinopril—systemic scleroderma	4.71e-05	0.00145	CcSEcCtD
Fluocinolone Acetonide—Infection—Azathioprine—systemic scleroderma	4.71e-05	0.00145	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Mycophenolic acid—systemic scleroderma	4.7e-05	0.00145	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Leflunomide—systemic scleroderma	4.67e-05	0.00144	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	4.66e-05	0.00143	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Lisinopril—systemic scleroderma	4.62e-05	0.00142	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Mycophenolate mofetil—systemic scleroderma	4.57e-05	0.00141	CcSEcCtD
Fluocinolone Acetonide—Cough—Mycophenolic acid—systemic scleroderma	4.57e-05	0.00141	CcSEcCtD
Fluocinolone Acetonide—Back pain—Lisinopril—systemic scleroderma	4.56e-05	0.0014	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Pentoxifylline—systemic scleroderma	4.56e-05	0.0014	CcSEcCtD
Fluocinolone Acetonide—Rash—Pentoxifylline—systemic scleroderma	4.52e-05	0.00139	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Pentoxifylline—systemic scleroderma	4.52e-05	0.00139	CcSEcCtD
Fluocinolone Acetonide—Headache—Pentoxifylline—systemic scleroderma	4.49e-05	0.00138	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Mycophenolic acid—systemic scleroderma	4.46e-05	0.00137	CcSEcCtD
Fluocinolone Acetonide—Infection—Leflunomide—systemic scleroderma	4.45e-05	0.00137	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Lisinopril—systemic scleroderma	4.44e-05	0.00137	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Mycophenolate mofetil—systemic scleroderma	4.43e-05	0.00136	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Leflunomide—systemic scleroderma	4.39e-05	0.00135	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Mometasone—systemic scleroderma	4.38e-05	0.00135	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	4.32e-05	0.00133	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Captopril—systemic scleroderma	4.3e-05	0.00132	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	4.28e-05	0.00132	CcSEcCtD
Fluocinolone Acetonide—Oedema—Mycophenolic acid—systemic scleroderma	4.27e-05	0.00131	CcSEcCtD
Fluocinolone Acetonide—Nausea—Pentoxifylline—systemic scleroderma	4.26e-05	0.00131	CcSEcCtD
Fluocinolone Acetonide—Infection—Mycophenolic acid—systemic scleroderma	4.24e-05	0.00131	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Lisinopril—systemic scleroderma	4.24e-05	0.0013	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Mometasone—systemic scleroderma	4.23e-05	0.0013	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Mycophenolate mofetil—systemic scleroderma	4.19e-05	0.00129	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Mycophenolic acid—systemic scleroderma	4.19e-05	0.00129	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Mycophenolate mofetil—systemic scleroderma	4.16e-05	0.00128	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Mycophenolate mofetil—systemic scleroderma	4.13e-05	0.00127	CcSEcCtD
Fluocinolone Acetonide—Cough—Lisinopril—systemic scleroderma	4.11e-05	0.00127	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Methotrexate—systemic scleroderma	4.1e-05	0.00126	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	4.09e-05	0.00126	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	4.08e-05	0.00126	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	4.05e-05	0.00124	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Lisinopril—systemic scleroderma	4.01e-05	0.00124	CcSEcCtD
Fluocinolone Acetonide—Back pain—Mycophenolate mofetil—systemic scleroderma	4e-05	0.00123	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Mometasone—systemic scleroderma	3.93e-05	0.00121	CcSEcCtD
Fluocinolone Acetonide—Rash—Mometasone—systemic scleroderma	3.9e-05	0.0012	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Mometasone—systemic scleroderma	3.9e-05	0.0012	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	3.89e-05	0.0012	CcSEcCtD
Fluocinolone Acetonide—Headache—Mometasone—systemic scleroderma	3.88e-05	0.00119	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	3.87e-05	0.00119	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Betamethasone—Mometasone—systemic scleroderma	3.85e-05	0.0379	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Dexamethasone—Mometasone—systemic scleroderma	3.85e-05	0.0379	CbGdCrCtD
Fluocinolone Acetonide—Oedema—Lisinopril—systemic scleroderma	3.85e-05	0.00118	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Captopril—systemic scleroderma	3.84e-05	0.00118	CcSEcCtD
Fluocinolone Acetonide—Pain—Leflunomide—systemic scleroderma	3.83e-05	0.00118	CcSEcCtD
Fluocinolone Acetonide—Infection—Lisinopril—systemic scleroderma	3.82e-05	0.00118	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Azathioprine—systemic scleroderma	3.75e-05	0.00115	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Captopril—systemic scleroderma	3.72e-05	0.00114	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Mycophenolate mofetil—systemic scleroderma	3.71e-05	0.00114	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	3.69e-05	0.00113	CcSEcCtD
Fluocinolone Acetonide—Nausea—Mometasone—systemic scleroderma	3.67e-05	0.00113	CcSEcCtD
Fluocinolone Acetonide—Pain—Mycophenolic acid—systemic scleroderma	3.65e-05	0.00112	CcSEcCtD
Fluocinolone Acetonide—Cough—Mycophenolate mofetil—systemic scleroderma	3.6e-05	0.00111	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Captopril—systemic scleroderma	3.59e-05	0.00111	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Leflunomide—systemic scleroderma	3.54e-05	0.00109	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	3.52e-05	0.00108	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	3.51e-05	0.00108	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Azathioprine—systemic scleroderma	3.49e-05	0.00107	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Captopril—systemic scleroderma	3.45e-05	0.00106	CcSEcCtD
Fluocinolone Acetonide—Rash—Captopril—systemic scleroderma	3.43e-05	0.00105	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Captopril—systemic scleroderma	3.42e-05	0.00105	CcSEcCtD
Fluocinolone Acetonide—Headache—Captopril—systemic scleroderma	3.4e-05	0.00105	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Mycophenolic acid—systemic scleroderma	3.38e-05	0.00104	CcSEcCtD
Fluocinolone Acetonide—Oedema—Mycophenolate mofetil—systemic scleroderma	3.37e-05	0.00104	CcSEcCtD
Fluocinolone Acetonide—Infection—Mycophenolate mofetil—systemic scleroderma	3.35e-05	0.00103	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	3.32e-05	0.00102	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	3.31e-05	0.00102	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Leflunomide—systemic scleroderma	3.3e-05	0.00102	CcSEcCtD
Fluocinolone Acetonide—Pain—Lisinopril—systemic scleroderma	3.29e-05	0.00101	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Azathioprine—systemic scleroderma	3.24e-05	0.000998	CcSEcCtD
Fluocinolone Acetonide—Nausea—Captopril—systemic scleroderma	3.23e-05	0.000993	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Leflunomide—systemic scleroderma	3.17e-05	0.000975	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Prednisone—systemic scleroderma	3.16e-05	0.000973	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Azathioprine—systemic scleroderma	3.14e-05	0.000965	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	3.12e-05	0.00096	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	3.07e-05	0.000945	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Leflunomide—systemic scleroderma	3.06e-05	0.000943	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Lisinopril—systemic scleroderma	3.04e-05	0.000936	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Mycophenolic acid—systemic scleroderma	3.02e-05	0.00093	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Azathioprine—systemic scleroderma	3.02e-05	0.000928	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Prednisone—systemic scleroderma	3.01e-05	0.000925	CcSEcCtD
Fluocinolone Acetonide—Infestation—Methotrexate—systemic scleroderma	2.99e-05	0.000921	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Methotrexate—systemic scleroderma	2.99e-05	0.000921	CcSEcCtD
Fluocinolone Acetonide—Rash—Azathioprine—systemic scleroderma	2.99e-05	0.00092	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Azathioprine—systemic scleroderma	2.99e-05	0.000919	CcSEcCtD
Fluocinolone Acetonide—Headache—Azathioprine—systemic scleroderma	2.97e-05	0.000914	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Leflunomide—systemic scleroderma	2.96e-05	0.000911	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Mycophenolic acid—systemic scleroderma	2.92e-05	0.000899	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	2.91e-05	0.000896	CcSEcCtD
Fluocinolone Acetonide—Pain—Mycophenolate mofetil—systemic scleroderma	2.88e-05	0.000887	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Leflunomide—systemic scleroderma	2.85e-05	0.000876	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Prednisone—systemic scleroderma	2.84e-05	0.000875	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Lisinopril—systemic scleroderma	2.83e-05	0.000872	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Mycophenolic acid—systemic scleroderma	2.83e-05	0.000869	CcSEcCtD
Fluocinolone Acetonide—Rash—Leflunomide—systemic scleroderma	2.82e-05	0.000869	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Leflunomide—systemic scleroderma	2.82e-05	0.000868	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Prednisone—systemic scleroderma	2.82e-05	0.000867	CcSEcCtD
Fluocinolone Acetonide—Nausea—Azathioprine—systemic scleroderma	2.82e-05	0.000867	CcSEcCtD
Fluocinolone Acetonide—Headache—Leflunomide—systemic scleroderma	2.81e-05	0.000863	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Prednisone—systemic scleroderma	2.8e-05	0.000862	CcSEcCtD
Fluocinolone Acetonide—Erythema—Prednisone—systemic scleroderma	2.8e-05	0.000862	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Lisinopril—systemic scleroderma	2.72e-05	0.000838	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Mycophenolic acid—systemic scleroderma	2.72e-05	0.000836	CcSEcCtD
Fluocinolone Acetonide—Rash—Mycophenolic acid—systemic scleroderma	2.69e-05	0.000829	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Mycophenolic acid—systemic scleroderma	2.69e-05	0.000828	CcSEcCtD
Fluocinolone Acetonide—Headache—Mycophenolic acid—systemic scleroderma	2.68e-05	0.000823	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	2.67e-05	0.00082	CcSEcCtD
Fluocinolone Acetonide—Nausea—Leflunomide—systemic scleroderma	2.66e-05	0.000818	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Prednisone—systemic scleroderma	2.64e-05	0.000812	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Lisinopril—systemic scleroderma	2.63e-05	0.00081	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Methotrexate—systemic scleroderma	2.59e-05	0.000797	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Lisinopril—systemic scleroderma	2.54e-05	0.000783	CcSEcCtD
Fluocinolone Acetonide—Nausea—Mycophenolic acid—systemic scleroderma	2.54e-05	0.000781	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Prednisone—systemic scleroderma	2.52e-05	0.000774	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Methotrexate—systemic scleroderma	2.51e-05	0.000773	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	2.48e-05	0.000764	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Lisinopril—systemic scleroderma	2.45e-05	0.000753	CcSEcCtD
Fluocinolone Acetonide—Rash—Lisinopril—systemic scleroderma	2.43e-05	0.000746	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Lisinopril—systemic scleroderma	2.42e-05	0.000746	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Methotrexate—systemic scleroderma	2.42e-05	0.000745	CcSEcCtD
Fluocinolone Acetonide—Headache—Lisinopril—systemic scleroderma	2.41e-05	0.000742	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Mycophenolate mofetil—systemic scleroderma	2.39e-05	0.000734	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Prednisone—systemic scleroderma	2.38e-05	0.000733	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Methotrexate—systemic scleroderma	2.38e-05	0.000731	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Methotrexate—systemic scleroderma	2.36e-05	0.000725	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Methotrexate—systemic scleroderma	2.34e-05	0.00072	CcSEcCtD
Fluocinolone Acetonide—Erythema—Methotrexate—systemic scleroderma	2.34e-05	0.00072	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	2.31e-05	0.00071	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Methotrexate—systemic scleroderma	2.29e-05	0.000705	CcSEcCtD
Fluocinolone Acetonide—Nausea—Lisinopril—systemic scleroderma	2.29e-05	0.000703	CcSEcCtD
Fluocinolone Acetonide—Oedema—Prednisone—systemic scleroderma	2.29e-05	0.000703	CcSEcCtD
Fluocinolone Acetonide—Infection—Prednisone—systemic scleroderma	2.27e-05	0.000699	CcSEcCtD
Fluocinolone Acetonide—Back pain—Methotrexate—systemic scleroderma	2.26e-05	0.000696	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Prednisone—systemic scleroderma	2.24e-05	0.00069	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Mycophenolate mofetil—systemic scleroderma	2.23e-05	0.000686	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Methotrexate—systemic scleroderma	2.21e-05	0.000679	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Mycophenolate mofetil—systemic scleroderma	2.14e-05	0.00066	CcSEcCtD
Fluocinolone Acetonide—Rash—Mycophenolate mofetil—systemic scleroderma	2.13e-05	0.000654	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	2.12e-05	0.000653	CcSEcCtD
Fluocinolone Acetonide—Headache—Mycophenolate mofetil—systemic scleroderma	2.11e-05	0.00065	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Methotrexate—systemic scleroderma	2.1e-05	0.000647	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Betamethasone—Prednisone—systemic scleroderma	2.1e-05	0.0207	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Dexamethasone—Prednisone—systemic scleroderma	2.1e-05	0.0207	CbGdCrCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.08e-05	0.000641	CcSEcCtD
Fluocinolone Acetonide—Cough—Methotrexate—systemic scleroderma	2.04e-05	0.000628	CcSEcCtD
Fluocinolone Acetonide—Nausea—Mycophenolate mofetil—systemic scleroderma	2e-05	0.000616	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Methotrexate—systemic scleroderma	1.99e-05	0.000613	CcSEcCtD
Fluocinolone Acetonide—Infection—Methotrexate—systemic scleroderma	1.9e-05	0.000584	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Methotrexate—systemic scleroderma	1.87e-05	0.000576	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Prednisone—systemic scleroderma	1.81e-05	0.000556	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	1.74e-05	0.000535	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Prednisone—systemic scleroderma	1.68e-05	0.000518	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	1.65e-05	0.000507	CcSEcCtD
Fluocinolone Acetonide—Pain—Methotrexate—systemic scleroderma	1.63e-05	0.000503	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Prednisone—systemic scleroderma	1.62e-05	0.000497	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Prednisone—systemic scleroderma	1.56e-05	0.000481	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Prednisone—systemic scleroderma	1.51e-05	0.000465	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Methotrexate—systemic scleroderma	1.51e-05	0.000465	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Prednisone—systemic scleroderma	1.45e-05	0.000447	CcSEcCtD
Fluocinolone Acetonide—Rash—Prednisone—systemic scleroderma	1.44e-05	0.000443	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Prednisone—systemic scleroderma	1.44e-05	0.000443	CcSEcCtD
Fluocinolone Acetonide—Headache—Prednisone—systemic scleroderma	1.43e-05	0.00044	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Methotrexate—systemic scleroderma	1.41e-05	0.000433	CcSEcCtD
Fluocinolone Acetonide—Nausea—Prednisone—systemic scleroderma	1.36e-05	0.000418	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Methotrexate—systemic scleroderma	1.35e-05	0.000416	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Methotrexate—systemic scleroderma	1.31e-05	0.000402	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Methotrexate—systemic scleroderma	1.26e-05	0.000389	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Methotrexate—systemic scleroderma	1.21e-05	0.000374	CcSEcCtD
Fluocinolone Acetonide—Rash—Methotrexate—systemic scleroderma	1.2e-05	0.000371	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Methotrexate—systemic scleroderma	1.2e-05	0.00037	CcSEcCtD
Fluocinolone Acetonide—Headache—Methotrexate—systemic scleroderma	1.2e-05	0.000368	CcSEcCtD
Fluocinolone Acetonide—Nausea—Methotrexate—systemic scleroderma	1.13e-05	0.000349	CcSEcCtD
